Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non-Small Cell Lung Cancer Patients in India
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non-Small Cell Lung Cancer Patients in India. Single-Arm Study to Evaluate the Safety of Lorlatinib in ALK Inhibitor-Treated
Unresectable Advanced and/or Recurrent ALK-Positive Non-Small Cell Lung Cancer Participants in India.
Category & Conditions: Cancer
Medicine: Lorbrena (lorlatinib)
ClinicalTrials.gov Identifier (NCT): NCT04541706
Protocol ID: B7461030
PrintDownloadOpen Plain Language Summary Result: Click here